share_log

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin製藥公司宣佈680萬美元公開發行定價
Quoin Pharmaceuticals ·  2024/12/20 13:00

ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), Series F warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs and Series G warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs at a combined purchase price of $0.45 per ADS and associated Series F and Series G warrants. The Series F warrants and Series G warrants will have an exercise price of $0.45 per share, will be exercisable immediately following the date of issuance and will expire in two years and five years, respectively, from their issuance.

弗吉尼亞州阿什本,2024年12月20日(環球新聞通訊社)—— Quoin Pharmaceuticals Ltd.(納斯達克:QNRX)(以下簡稱"公司"或"Quoin"),是一家專注於罕見和孤兒病的臨牀階段專業藥品公司,今天宣佈其"合理最佳努力"公開發行的定價,包括15,111,110股普通股,代表15,111,110股美國存托股份(「ADSs」)(或相應的預付認股權證),系列F認股權證可購買總計最多15,111,110股普通股,代表15,111,110股ADSs,系列G認股權證可購買總計最多15,111,110股普通股,代表15,111,110股ADSs,每股ADS及相關係列F和系列G認股權證的綜合購買價格爲0.45美元。系列F認股權證和系列G認股權證的行使價格爲每股0.45美元,將在發行之日後立即可行使,並將在自發行之日起分別兩年和五年到期。

Gross proceeds, before deducting placement agent fees and offering expenses, are expected to be approximately $6.8 million, and includes participation from certain of the Company's executive officers and directors. The closing of the offering is expected to occur on or about December 23, 2024, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the offering for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of its product candidates, working capital, future acquisitions and general capital expenditures.

在扣除代理費和發行費用之前,預計總收益約爲680萬美元,幷包括公司某些高管和董事的參與。發行的結束預計將在2024年12月23日左右進行,需滿足慣例結束條件。公司目前打算將發行的淨收益用於一般企業目的,其中可能包括營業費用、研究和開發,包括其產品候選者的臨牀和臨牀前測試、流動資金、未來收購和一般資本支出。

Maxim Group LLC is acting as sole placement agent for the offering.

Maxim Group LLC爲此次發行的唯一承銷商。

In addition, the Company has entered into privately negotiated agreements with the holders of certain existing outstanding warrants to purchase up to 7,002,500 ADSs (the "Prior Warrants") to, among other modifications, reduce the exercise price of such Prior Warrants from $1.60 per ADS to $0.45 per ADS and to extend the current expiration date of the Prior Warrants until December 23, 2029.

此外,公司已與某些現有已發行認股權證的持有者達成私下協商的協議,購買最多7,002,500股ADS("前期認股權證"),以進行其他修改,包括將前期認股權證的行使價格從每股1.60美元降低至每股0.45美元,並將前期認股權證的到期日期延長至2029年12月23日。

The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-283734), which was declared effective by the Securities and Exchange Commission (the "SEC") on December 20, 2024. The offering is being made only by means of a prospectus which is a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.

上述證券是根據修訂後的S-1表格註冊聲明進行發行的(備案號333-283734),該註冊聲明於2024年12月20日獲得證券交易委員會("SEC")的有效批准。此次發行僅通過包含在有效註冊聲明中的招股說明書進行。與此次發行相關的初步招股說明書已經提交給SEC。與本次發行相關的最終招股說明書副本將在可用時提交給SEC,並可從Maxim Group LLC獲取,地址爲紐約公園大道300號16層,郵政編碼10022,聯繫電話(212) 895-3745。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

本新聞稿不構成對出售或對購買本文所述任何證券的要約,也不應在任何州或其他法域中進行這些證券的銷售,其中此類要約、招攬或銷售在任何州或其他法域的證券法律規定下,在註冊或資格獲得之前將是非法的。

About Quoin Pharmaceuticals Ltd.

關於Quoin藥品有限公司。

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or LinkedIn for updates.

Quoin製藥有限公司是一家臨牀階段專科藥品公司,專注於開發和商業化治療稀有及孤兒疾病的治療產品。我們致力於滿足患者、家庭、社區和護理團隊的未滿足醫療需求。Quoin的創新產品線包括四個正在開發的產品,collectively potential target a broad number of rare and orphan indications, including Netherton syndrome, peeling skin syndrome, palmoplantar keratoderma, scleroderma, epidermolysis bullosa and others. 如需了解更多信息,請訪問:或LinkedIn進行更新。

Cautionary Note Regarding Forward Looking Statements

關於前瞻性聲明的警示說明

The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," "look forward to," and "will," among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the Company's ability to consummate the closing of the offering when intended and the intended use of proceeds, the Company's ability to satisfy closing conditions for the offering, the development of a safe and effective treatment for the Netherton Syndrome community and Quoin's belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the clinical studies may not generate the results anticipated, the Company ability to recruit additional pediatric subjects, or the clinical studies not generating data which is sufficiently robust and comprehensive to support an NDA filing and the Company's ability to obtain regulatory approvals. More detailed information about the risks and uncertainties affecting the Company is summarized in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

本公司提醒,本文發佈中的聲明並非對歷史事實的描述,而是1995年《私人證券訴訟改革法案》意義上的前瞻性聲明。前瞻性聲明可以通過引用未來事件或情況的詞語來識別,例如「預計」、「打算」、「計劃」、「預期」、「相信」、「期待」和「將」等等。所有反映公司對未來的預期、假設、預測、信念或意見的聲明,除了歷史事實聲明之外,都是前瞻性聲明,包括但不限於與以下內容相關的聲明:公司在預定時間內完成本次發行的能力及籌集資金的預期用途,公司的能力滿足本次發行的成交條件,開發出一種安全有效的Netherton綜合症治療方案,以及時Quoin對其開發產品的信念,即其產品有潛力共同針對廣泛的罕見及孤兒病症,包括Netherton綜合症、剝皮皮膚綜合症、掌蹠角化病、硬皮病、表皮鬆解性大皰症等。由於這些聲明面臨風險和不確定性,實際結果可能與這些前瞻性聲明所表達或暗示的結果存在實質性差異。這些前瞻性聲明是基於本公司的當前預期,並涉及可能永遠無法實現或可能被證明不正確的假設。實際結果和事件的時機可能由於各種風險和不確定性,與這些前瞻性聲明中預期的存在實質性差異,包括但不限於,臨牀研究可能未能產生預期的結果,公司招募額外兒童受試者的能力,或臨牀研究未能產生足夠穩健和全面的數據以支持NDA申請,以及公司獲得監管批准的能力。關於影響公司的風險和不確定性的詳細信息已在公司截至2023年12月31日的10-K年報和公司已向SEC提交及可能繼續提交的其他文件中進行了總結。任何人都不應過分依賴這些僅在做出時有效的前瞻性聲明。本公司沒有義務更新這些聲明,以反映自作出聲明以來發生的事件或存在的情況,除非法律要求。

Investor Relations Contact:
Investor Relations
PCG Advisory
Jeff Ramson
646-863-6893
jramson@pcgadvisory.com

投資者關係聯繫:
投資者關係
PCG顧問公司
傑夫·拉姆森
646-863-6893
jramson@pcgadvisory.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論